KR102364134B1 - 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 - Google Patents
디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 Download PDFInfo
- Publication number
- KR102364134B1 KR102364134B1 KR1020207000676A KR20207000676A KR102364134B1 KR 102364134 B1 KR102364134 B1 KR 102364134B1 KR 1020207000676 A KR1020207000676 A KR 1020207000676A KR 20207000676 A KR20207000676 A KR 20207000676A KR 102364134 B1 KR102364134 B1 KR 102364134B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- group
- compound
- methyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*1C2(C*(C3)I)C3COCC12 Chemical compound C*1C2(C*(C3)I)C3COCC12 0.000 description 15
- ZCDJIDOPTNDVAQ-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)C3CN2C(OC(C)(C)C)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)C3CN2C(OC(C)(C)C)=O)[n](cccn2)c2n1 ZCDJIDOPTNDVAQ-UHFFFAOYSA-N 0.000 description 2
- PALOETWSZLRKLX-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2c(C3CC3)[o]cn2)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2c(C3CC3)[o]cn2)=O)[n](cccn2)c2n1 PALOETWSZLRKLX-UHFFFAOYSA-N 0.000 description 1
- VDKJCAWGDJJKNL-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2nc(OC)ccc2Cl)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2nc(OC)ccc2Cl)=O)[n](cccn2)c2n1 VDKJCAWGDJJKNL-UHFFFAOYSA-N 0.000 description 1
- OGGHXOJOVOYBOH-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2nc(OC)ccc2F)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2nc(OC)ccc2F)=O)[n](cccn2)c2n1 OGGHXOJOVOYBOH-UHFFFAOYSA-N 0.000 description 1
- IQJPMLROUYSIIJ-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2COC3)CC3N2C(c2nc(OC(F)F)ccc2)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2COC3)CC3N2C(c2nc(OC(F)F)ccc2)=O)[n](cccn2)c2n1 IQJPMLROUYSIIJ-UHFFFAOYSA-N 0.000 description 1
- BRQUOSSZQFFDTO-UHFFFAOYSA-N CC(c1c(-c(cc2)ccc2Cl)nc2nccc[n]12)N(CC1CC2)CC2N1C(OC(C)(C)C)=O Chemical compound CC(c1c(-c(cc2)ccc2Cl)nc2nccc[n]12)N(CC1CC2)CC2N1C(OC(C)(C)C)=O BRQUOSSZQFFDTO-UHFFFAOYSA-N 0.000 description 1
- DCIMLHHFMXLZES-UHFFFAOYSA-N CN(C(CC1)C2)C1CN2I Chemical compound CN(C(CC1)C2)C1CN2I DCIMLHHFMXLZES-UHFFFAOYSA-N 0.000 description 1
- GXIMUJOQZCMEFY-UHFFFAOYSA-N CN1C(CC2)CNC2C1 Chemical compound CN1C(CC2)CNC2C1 GXIMUJOQZCMEFY-UHFFFAOYSA-N 0.000 description 1
- IDQHHCOWPCFYIN-UHFFFAOYSA-N COc(nc1C(N2C3COCC2CN(Cc2c(-c(cc4)ccc4Cl)nc4nccc[n]24)C3)=O)ccc1F Chemical compound COc(nc1C(N2C3COCC2CN(Cc2c(-c(cc4)ccc4Cl)nc4nccc[n]24)C3)=O)ccc1F IDQHHCOWPCFYIN-UHFFFAOYSA-N 0.000 description 1
- PNRHBIXNPFBEKL-UHFFFAOYSA-N COc1nc(C(N2C3COCC2CN(Cc2c(-c(cc4)ccc4Cl)nc4nccc[n]24)C3)=O)ccc1 Chemical compound COc1nc(C(N2C3COCC2CN(Cc2c(-c(cc4)ccc4Cl)nc4nccc[n]24)C3)=O)ccc1 PNRHBIXNPFBEKL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17176046 | 2017-06-14 | ||
| EP17176046.5 | 2017-06-14 | ||
| EP17193252 | 2017-09-26 | ||
| EP17193252.8 | 2017-09-26 | ||
| PCT/EP2018/064977 WO2018228907A1 (de) | 2017-06-14 | 2018-06-07 | Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200014915A KR20200014915A (ko) | 2020-02-11 |
| KR102364134B1 true KR102364134B1 (ko) | 2022-02-18 |
Family
ID=62492660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207000676A Active KR102364134B1 (ko) | 2017-06-14 | 2018-06-07 | 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 |
Country Status (36)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018536693A (ja) | 2015-12-10 | 2018-12-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 睡眠関連呼吸障害を治療するためのＴＡＳＫ−１およびＴＡＳＫ−２チャネルの遮断薬としての２−フェニル−３−（ピペラジノメチル）イミダゾ［１，２−ａ］ピリジン誘導体 |
| JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| TW202108139A (zh) * | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合 |
| PE20221025A1 (es) | 2019-11-06 | 2022-06-16 | Bayer Ag | Inhibidores de los receptores a2c adrenergicos |
| WO2022008426A1 (en) * | 2020-07-06 | 2022-01-13 | Bayer Aktiengesellschaft | Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonist with a task1/3 channel blocker for the treatment of sleep apnea |
| GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
| CN118434415A (zh) | 2021-12-22 | 2024-08-02 | 拜耳公司 | 用于治疗睡眠呼吸暂停的task1/3通道阻断剂与毒蕈碱型受体拮抗剂的结合物 |
| US20250057845A1 (en) | 2021-12-22 | 2025-02-20 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea |
| JP2024545289A (ja) | 2021-12-22 | 2024-12-05 | バイエル・アクチエンゲゼルシヤフト | 睡眠時無呼吸の治療のためのｔａｓｋ１／３チャネル遮断薬とノルエピネフリン再取込み阻害薬との組合せ |
| EP4460307A1 (en) | 2022-01-07 | 2024-11-13 | Bayer Aktiengesellschaft | 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea |
| EP4460298A1 (en) | 2022-01-07 | 2024-11-13 | Bayer Aktiengesellschaft | Alpha2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA |
| WO2025068514A1 (en) | 2023-09-28 | 2025-04-03 | Bayer Aktiengesellschaft | Substituted heterocyclic carboxamindes and use thereof |
| CN117959293B (zh) * | 2024-01-18 | 2025-05-13 | 香港大学深圳医院 | 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037914A1 (en) | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| WO2014187922A1 (en) | 2013-05-24 | 2014-11-27 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
| WO2016084783A1 (ja) | 2014-11-26 | 2016-06-02 | 株式会社村田製作所 | 電子部品の製造方法、電子部品および電子装置 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| WO2002002557A2 (en) | 2000-06-30 | 2002-01-10 | Neurogen Corporation | 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands |
| GB0017256D0 (en) | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
| US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| BRPI0710946A2 (pt) | 2006-04-27 | 2012-03-06 | Sanofi-Aventis Deutschland Gmbh | inibidores dos canais de Íon task-1 e task-3 |
| EP2049110B1 (en) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| CA2724842A1 (en) | 2008-05-19 | 2009-11-26 | Sunovion Pharmaceuticals Inc. | Imidazo[1,2-a]pyridine compounds |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| CA2793086C (en) | 2010-03-18 | 2018-08-21 | Institut Pasteur Korea | Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| TW201242965A (en) | 2011-02-01 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | Ring-fused heterocyclic derivative |
| EP2691392A1 (en) | 2011-03-31 | 2014-02-05 | EMBLEM Technology Transfer GmbH | Imidazo [1,2-a]pyridine compounds for use in therapy |
| KR102104125B1 (ko) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| MX2014002968A (es) | 2011-09-12 | 2014-07-09 | Sanofi Sa | 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden. |
| AU2011376721B2 (en) | 2011-09-16 | 2017-06-08 | Sanofi | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| JP6126135B2 (ja) | 2012-02-03 | 2017-05-10 | サノフイ | 縮合ピロールカルボキサミド及びその医薬としてのその使用 |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| JP2018012645A (ja) | 2014-11-26 | 2018-01-25 | 持田製薬株式会社 | 新規ジアザビシクロ誘導体 |
| US9994570B2 (en) * | 2014-11-26 | 2018-06-12 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
| US10000499B2 (en) | 2014-11-26 | 2018-06-19 | Merck Sharp & Dohme Corp. | Methyl diazepane orexin receptor antagonists |
| JP2018016544A (ja) | 2014-12-03 | 2018-02-01 | 持田製薬株式会社 | 新規ジアザビシクロ［２．２．２］オクタン誘導体 |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
| JP2018536693A (ja) | 2015-12-10 | 2018-12-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 睡眠関連呼吸障害を治療するためのＴＡＳＫ−１およびＴＡＳＫ−２チャネルの遮断薬としての２−フェニル−３−（ピペラジノメチル）イミダゾ［１，２−ａ］ピリジン誘導体 |
| JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| PE20211285A1 (es) | 2018-11-27 | 2021-07-19 | Bayer Ag | Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios |
| TW202108139A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合 |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
-
2017
- 2017-06-16 JO JOP/2019/0284A patent/JOP20190284A1/ar unknown
-
2018
- 2018-06-07 MY MYPI2019007414A patent/MY204293A/en unknown
- 2018-06-07 JP JP2019569416A patent/JP6896113B2/ja not_active Expired - Fee Related
- 2018-06-07 CN CN202211200627.2A patent/CN115583959B/zh active Active
- 2018-06-07 US US16/622,233 patent/US11098063B2/en active Active
- 2018-06-07 BR BR112019026450-7A patent/BR112019026450A2/pt not_active Application Discontinuation
- 2018-06-07 CN CN202211199746.0A patent/CN115554299A/zh active Pending
- 2018-06-07 GE GEAP202115256A patent/GEAP202115256A/en unknown
- 2018-06-07 KR KR1020207000676A patent/KR102364134B1/ko active Active
- 2018-06-07 CA CA3066942A patent/CA3066942A1/en active Pending
- 2018-06-07 EA EA202090043A patent/EA202090043A1/ru unknown
- 2018-06-07 CU CU2019000101A patent/CU24603B1/es unknown
- 2018-06-07 HR HRP20240678TT patent/HRP20240678T1/hr unknown
- 2018-06-07 CR CR20190563A patent/CR20190563A/es unknown
- 2018-06-07 HU HUE18728646A patent/HUE066512T2/hu unknown
- 2018-06-07 UA UAA202000222A patent/UA125186C2/uk unknown
- 2018-06-07 CN CN201880039548.3A patent/CN110719911B/zh active Active
- 2018-06-07 WO PCT/EP2018/064977 patent/WO2018228907A1/de not_active Ceased
- 2018-06-07 MX MX2019014983A patent/MX2019014983A/es unknown
- 2018-06-07 GE GEAP201815256A patent/GEP20227366B/en unknown
- 2018-06-07 RS RS20240581A patent/RS65543B1/sr unknown
- 2018-06-07 AU AU2018283331A patent/AU2018283331B2/en not_active Ceased
- 2018-06-07 PE PE2019002541A patent/PE20200016A1/es unknown
- 2018-06-07 SG SG11201911508XA patent/SG11201911508XA/en unknown
- 2018-06-07 CN CN202211200547.7A patent/CN115554300B/zh active Active
- 2018-06-07 PL PL18728646.3T patent/PL3638675T3/pl unknown
- 2018-06-07 EP EP18728646.3A patent/EP3638675B1/de active Active
- 2018-06-07 NZ NZ758821A patent/NZ758821A/en unknown
- 2018-06-07 MA MA49368A patent/MA49368B1/fr unknown
- 2018-06-07 ES ES18728646T patent/ES2985167T3/es active Active
- 2018-06-12 TW TW107120117A patent/TWI801388B/zh active
- 2018-06-13 AR ARP180101619A patent/AR112099A1/es not_active Application Discontinuation
- 2018-06-14 UY UY0001037773A patent/UY37773A/es not_active Application Discontinuation
-
2019
- 2019-12-02 IL IL271117A patent/IL271117B/en unknown
- 2019-12-11 MX MX2022012716A patent/MX2022012716A/es unknown
- 2019-12-12 CO CONC2019/0014047A patent/CO2019014047A2/es unknown
- 2019-12-12 CL CL2019003650A patent/CL2019003650A1/es unknown
- 2019-12-12 NI NI201900126A patent/NI201900126A/es unknown
- 2019-12-12 EC ECSENADI201988492A patent/ECSP19088492A/es unknown
- 2019-12-13 DO DO2019000308A patent/DOP2019000308A/es unknown
- 2019-12-13 PH PH12019502828A patent/PH12019502828A1/en unknown
-
2021
- 2021-06-04 JP JP2021094338A patent/JP2021127346A/ja active Pending
- 2021-07-16 US US17/305,927 patent/US12180227B2/en active Active
-
2024
- 2024-11-21 US US18/955,853 patent/US20250154175A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037914A1 (en) | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| WO2014187922A1 (en) | 2013-05-24 | 2014-11-27 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
| WO2016084783A1 (ja) | 2014-11-26 | 2016-06-02 | 株式会社村田製作所 | 電子部品の製造方法、電子部品および電子装置 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102364134B1 (ko) | 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 | |
| KR102444687B1 (ko) | 치환된 디아자헤테로비시클릭 화합물 및 그의 용도 | |
| US10414765B2 (en) | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same | |
| US11208422B2 (en) | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | |
| HK40085266A (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40085269A (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40085266B (zh) | 二氮杂双环取代的咪唑并嘧啶及其用於治疗呼吸障碍的用途 | |
| HK40085267A (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40015098B (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| HK40015098A (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| EA040559B1 (ru) | Диазабициклические замещенные имидазопиримидины и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200109 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210324 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20210324 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210726 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20211124 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220214 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220215 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |